Baker Bros. Advisors LP Immatics N.V. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 7,275,830 shares of IMTX stock, worth $33.7 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
7,275,830
Previous 6,443,398
12.92%
Holding current value
$33.7 Million
Previous $73.5 Million
29.64%
% of portfolio
0.57%
Previous 0.79%
Shares
10 transactions
Others Institutions Holding IMTX
# of Institutions
92Shares Held
82.1MCall Options Held
313KPut Options Held
377K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.6MShares$49.1 Million0.05% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$43.4 Million2.23% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$30.3 Million0.76% of portfolio
-
Vestal Point Capital, LP New York, NY6.28MShares$29.1 Million2.65% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.41MShares$25.1 Million1.47% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $353M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...